— Presentation on Monday, February 8, 2016, at 9:00 a.m. ET —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 1, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the 18th
Annual BIO CEO & Investor Conference in New York City on Monday,
February 8, 2016, at 9:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible from the
Investor Relations section of the Aimmune website at www.aimmune.com.
A replay of the webcast will be available for 14 days following the
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for peanut allergy and other food
allergies. The company’s characterized oral desensitization
immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT),
uses rigorously characterized product candidates with gradual,
controlled up-dosing protocols to obtain clinically meaningful
desensitization to food allergens. In early 2016, Aimmune Therapeutics
initiated the Phase 3 PALISADE trial of its lead product, AR101 for the
treatment of peanut allergy, one of the most common food allergies.
AR101 has received the FDA’s Breakthrough Therapy Designation for the
desensitization of peanut-allergic patients 4-17 years of age. For more
information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160201005363/en/
Source: Aimmune Therapeutics, Inc.
Stern Investor Relations
Beth DelGiacco, 212-362-1200